Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-188 in Advanced or Metastatic Solid Tumors
NCT07205718Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-188 in solid tumor, head and neck squamous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), gastroesophageal adenocarcinoma, sponsored by Takeda. Started Nov 2025; status: recruiting.
02
Drugs
TAK-188
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07205718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205718.